NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries

CompletedN/A

Sponsor: Biogen

Conditions: Progressive Multifocal Leukoencephalopathy

Interventions: Tysabri

Countries: United States

The primary purpose of this study is to estimate the incidence of progressive multifocal leukoencephalopathy (PML) among patients who switched to Tysabri from disease modifying therapies (DMTs), including newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate). Researchers will also look to estimate the incidence of other serious opportunistic infections among patients who switch to Tysabri from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate)

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Key Inclusion Criteria:

* All TOUCH and available EU MS registry participants who have switched from DMTs (including fingolimod, dimethyl fumarate, teriflunomide, interferon beta and glatiramer acetate) and have one or more infusion(s) of Tysabri.

Key Exclusion Criteria:

* Not applicable

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Locations (1)

Cambridge, Massachusetts, United States